153 completed, 16 recruiting, 16 unknown, 12 terminated. 214 Phase 1, 67 Phase 2.
Follow Insulin Resistance: new trials by email Literature Review of Insulin Resistance trials Research Report on Insulin Resistance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| cfMSC Therapy for Diabetes cfMSC therapy for diabetes - Type II Diabetes Mellitus | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Studies of Insulin and Glucagon Action in the Liver Glucagon, Saline (placebo) - Diabetes (DM) | Phase 1 / Phase 2 | Not yet recruiting | Duke University | 40 | 2026-10-01 | 2026-08-05 |
| Alpelisib Challenge Test (ACT) Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp - Insulin Resistance, Type 2 Diabetes | Phase 1 | Recruiting | Columbia University | 15 | 2026-09-02 | 2026-09-03 |
| Effect of Insulin Lowering on Lipogenesis Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70% - Hyperinsulinemia, Insulin Resistance | Phase 1 | Recruiting | Columbia University | 25 | 2026-07-01 | 2026-07-06 |
| Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury Regular Insulin, 0.9 % Normal Saline - Spinal Cord Injury | Phase 1 | Recruiting | HealthPartners Institute | 12 | 2026-02-20 | 2026-09-15 |
| A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin - Type 1 Diabetes | Phase 1 | Recruiting | Portal Diabetes, Inc. | 25 | 2026-02-10 | 2026-04-28 |
| A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects PATAS Trifluoroacetate, Placebo - Type 2 Diabetes | Phase 1 | Recruiting | AdipoPharma LLC | 56 | 2026-01-27 | 2026-09-29 |
| Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution - Diabetes (DM) | Phase 1 | Recruiting | David D'Alessio, M.D. | 30 | 2025-12-30 | 2026-10-01 |
| Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin - Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus | Phase 1 | Completed | Stanford University | 10 | 2025-10-28 | 2026-07-08 |
| Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline - Healthy | Phase 1 | Withdrawn | HealthPartners Institute | 2025-08-30 | 2025-11-25 | |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus Maridebart cafraglutide, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Active not recruiting | Amgen | 56 | 2025-08-05 | 2026-06-12 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Retatrutide, Semaglutide, Placebo - Diabetes Mellitus, Insulin Sensitivity | Phase 1 | Active not recruiting | Eli Lilly and Company | 95 | 2025-06-02 | 2026-10-06 |
| Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d), Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d) - Gestational Diabetes Mellitus (GDM), Oxidative Stress | Phase 1 / Phase 2 | Not yet recruiting | University of Kasdi Merbah | 200 | 2025-05-01 | 2025-03-05 |
| Effect of NAE on Polycystic Ovarian Syndrome (PCOS) Herbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg - Polycystic Ovarian Syndrome (PCOS), Infertility | Phase 1 | Completed | Jinnah Sindh Medical University | 116 | 2025-04-10 | 2026-06-22 |
| Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause Hyperbaric oxygen therapy, Hypoglycemic Drug - Insulin Resistance Syndrome | Phase 1 / Phase 2 | Recruiting | Cairo University | 40 | 2025-01-28 | 2025-02-04 |
| Aging Resilience Through Microbiota Optimization and Regulation FMT capsule, Placebo Capsule(s) - Resilience, Cognitive Function and Well-Being | Phase 1 | Active not recruiting | Gonzalo Jorquera, PhD | 80 | 2025-01-10 | 2026-07-29 |
| Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome A fiixed combination of Chinese herbal medicine, Laser acupuncture - Obesity, Metabolic Syndrome | Phase 1 / Phase 2 | Recruiting | Chang Gung Memorial Hospital | 200 | 2024-11-20 | 2024-11-25 |
| Diazoxide Suppression Test P&F Study Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia | Phase 1 | Terminated | Columbia University | 1 | 2024-10-23 | 2026-08-07 |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus LY3209590 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 15 | 2024-10-10 | 2026-03-24 |
Showing 20 of 214. Sign in to see all of them.
Metabolic Syndrome (52) · Obesity (52) · Diabetes Mellitus, Type 2 (41) · Diabetes Mellitus (40) · Diabetes Mellitus, Type 1 (15) · Inflammation (13) · Hyperinsulinism (12) · Prediabetic State (12) · Hypertension (11) · Overweight (10) · Non-alcoholic Fatty Liver Disease (9) · Polycystic Ovary Syndrome (9) · Dyslipidemias (5) · Glucose Intolerance (5)
Nutritional and Metabolic Diseases (214) · Glucose Metabolism Disorders (210) · Metabolic Diseases (209) · Hyperinsulinism (202) · Endocrine System Diseases (104) · Pathological Conditions, Signs and Symptoms (74) · Signs and Symptoms (64) · Body Weight (58) · Nutrition Disorders (57) · Diabetes Mellitus (56) · Overnutrition (56) · Overweight (46) · Immune System Diseases (21) · Urogenital Diseases (17)
Insulin (21) · Sodium Chloride (10) · Metformin (8) · Glucose (7) · Glucagon (6) · Insulin Lispro (6) · Exercise (5) · Saline Solution (5) · Insulin, Regular, Human (4) · Octreotide (4) · Rosiglitazone (4) · Alpelisib (3) · Diazoxide (3) · Human Growth Hormone (3) · Incretins (3)
Columbia University (11) · Vanderbilt University Medical Center (8) · Mayo Clinic (5) · Stanford University (5) · Halozyme Therapeutics (4) · Albert Einstein College of Medicine (3) · Eli Lilly and Company (3) · Gan and Lee Pharmaceuticals, USA (3) · Hanoi Medical University (3) · National Center for Complementary and Integrative Health (NCCIH) (3) · Pennington Biomedical Research Center (3) · University of Aarhus (3) · University of California, San Francisco (3) · Washington University School of Medicine (3) · Yungjin Pharm. Co., Ltd. (3)
United States (126) · Canada (14) · Germany (11) · United Kingdom (7) · Denmark (4) · Netherlands (4) · Sweden (4) · Vietnam (3) · Australia (2) · Brazil (2) · China (2) · France (2) · Indonesia (2) · Israel (2) · Pakistan (2)
Joshua R Cook, MD, PhD (9) · Dominic Reeds, MD (3) · Bruno Geloneze, MD, PhD (2) · Burton Wice, PhD (2) · Cyndya Shibao, MD (2) · David D'Alessio, MD (2) · Dwight R. Stickney, MD (2) · Jack A Yanovski, M.D. (2) · Jia Lu, PhD (2) · Joerg Schirra, MD (2) · Kimberly Byrnes, PhD (2) · Kyung-Sang Yu, Professor (2)
PMID 37735841, PMID 19475464, PMID 15220351, PMID 16818482, PMID 17065354, PMID 17283239, PMID 18400730, PMID 18491071, PMID 18825363, PMID 19064532, PMID 19142567, PMID 19337387, PMID 19459762, PMID 19487105, PMID 19500003, PMID 19816674, PMID 19875605, PMID 19931408, PMID 20307398, PMID 20551965, PMID 20833991, PMID 21233083, PMID 21480966, PMID 21677059, PMID 21714645, PMID 21714890, PMID 21715514, PMID 21865361, PMID 21865944, PMID 22011412, PMID 22140269, PMID 22522617, PMID 22647517, PMID 22721966, PMID 22743313, PMID 22775199, PMID 23043164, PMID 23111651, PMID 23220074, PMID 23303873, PMID 23361157, PMID 23593417, PMID 23638799, PMID 23713767, PMID 24074360, PMID 24130354, PMID 24183983, PMID 24191286, PMID 24212451, PMID 24328357
K12DK133995 (3), K23DK140614 (3), P30DK063608 (3), 1RC1DK086163-01 (1), 2009 (1), 2014 (1), 2019 (1), K23GM100273 (1), K23HL103976 (1), K23HL159292 (1), R01DK047936 (1), R01DK051729 (1), R01DK059358 (1), R01DK061644 (1), R01DK065515 (1)